First AD

Second AD

Data from the following clinical trials are discussed:

223: Molecular Characterization of Clinical Response and Relapse in Patients with 

m ND-AML Treated with Ivo+AZA in the AGILE Study

61: Phase I/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in Patients (pts) with Newly Diagnosed (ND) Older/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed/Refractory (R/R) AML

2746: Phase Ib/2 Study of Oral Decitabine/Cedazuridine (ASTX727) and Venetoclax in Combination with the Targeted Mutant IDH1 Inhibitor Ivosidenib or the Targeted Mutant IDH2 Inhibitor Enasidenib in IDH Mutated Acute Myeloid Leukemia

2758: A Phase 1/2 Dose Escalation Study of the Myeloid Kinase Inhibitor HM43239 in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Supported in part by Amgen Oncology, Servier, and Takeda Oncology. Content developed independently by OncLive®.

Hematologic Oncology

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

The Talk

® The TALK features a group of subject matter experts discussing key datasets and exciting updates from recent oncology conferences in various cancer types. These video programs are designed to highlight important areas of research and hot topics in the field of breast cancer, lung cancer, and multiple myeloma, among specialties. 

Leukemia: A Review of Data from the ASH 2022 Meeting

The University of Texas MD Anderson Cancer Center

Cancer Centers

Partner

Cleveland Clinic

Shared insight on recently updated data in acute myeloid leukemia following the ASH 2022 annual meeting.

Acute Myeloid Leukemia: Updates From The ASH 2022 Annual Meeting